JP2019509014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019509014A5 JP2019509014A5 JP2018526708A JP2018526708A JP2019509014A5 JP 2019509014 A5 JP2019509014 A5 JP 2019509014A5 JP 2018526708 A JP2018526708 A JP 2018526708A JP 2018526708 A JP2018526708 A JP 2018526708A JP 2019509014 A5 JP2019509014 A5 JP 2019509014A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- polypeptide
- binding
- human
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258701P | 2015-11-23 | 2015-11-23 | |
| US62/258,701 | 2015-11-23 | ||
| US201562263760P | 2015-12-07 | 2015-12-07 | |
| US62/263,760 | 2015-12-07 | ||
| US201562267343P | 2015-12-15 | 2015-12-15 | |
| US62/267,343 | 2015-12-15 | ||
| US201662320738P | 2016-04-11 | 2016-04-11 | |
| US62/320,738 | 2016-04-11 | ||
| US201662404779P | 2016-10-06 | 2016-10-06 | |
| US62/404,779 | 2016-10-06 | ||
| PCT/EP2016/078395 WO2017089334A1 (en) | 2015-11-23 | 2016-11-22 | Cd39 vascular isoform targeting agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019509014A JP2019509014A (ja) | 2019-04-04 |
| JP2019509014A5 true JP2019509014A5 (https=) | 2019-12-12 |
Family
ID=57391960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526708A Pending JP2019509014A (ja) | 2015-11-23 | 2016-11-22 | Ｃｄ３９血管アイソフォームターゲティング剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20190153113A1 (https=) |
| EP (1) | EP3380519A1 (https=) |
| JP (1) | JP2019509014A (https=) |
| AU (1) | AU2016359790A1 (https=) |
| CA (1) | CA3005986A1 (https=) |
| WO (1) | WO2017089334A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2238170B1 (en) | 2008-01-31 | 2016-11-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| IL269150B2 (en) | 2017-03-16 | 2025-04-01 | Innate Pharma | Cancer treatment preparations and methods |
| EP3622092A4 (en) * | 2017-05-11 | 2021-06-23 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF |
| MY202018A (en) * | 2017-07-31 | 2024-03-29 | Trishula Therapeutics Inc | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| BR112020006809A2 (pt) * | 2017-10-06 | 2020-10-06 | Innate Pharma | anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso |
| KR102781619B1 (ko) * | 2017-11-15 | 2025-03-14 | 이나뜨 파르마 에스.에이. | 암의 치료를 위한 인간 CD39 단백질의 ATPase 활성을 결합 및 저해하는 항체 |
| EP3737698A2 (en) * | 2018-01-10 | 2020-11-18 | BioInvent International AB | Novel combination and use of antibodies |
| EP3788079A4 (en) | 2018-05-03 | 2022-12-21 | Shanghai Epimab Biotherapeutics Co., Ltd. | ANTIBODIES WITH HIGH AFFINITY TO PD-1 AND LAG-3 AND BI-SPECIFIC BINDING PROTEINS PRODUCTION THEREOF |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| TW202012444A (zh) * | 2018-06-14 | 2020-04-01 | 美商貝斯以色列女執事醫療中心有限公司 | 用於通過外核苷酸酶抑制及抗體介導型靶標細胞攝入來預防或逆轉t 細胞耗竭之組合物及方法 |
| DK3807316T3 (da) | 2018-06-18 | 2024-07-29 | Innate Pharma | Sammensætninger og fremgangsmåder til behandling af cancer |
| MX2021008094A (es) | 2019-01-11 | 2021-09-21 | Omeros Corp | Metodos y composiciones para el tratamiento del cancer. |
| CN113795267A (zh) | 2019-03-12 | 2021-12-14 | 艾库斯生物科学有限公司 | 致癌基因驱动的癌症的治疗 |
| WO2020205527A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| MX2021012769A (es) | 2019-04-23 | 2021-11-18 | Innate Pharma | Anticuerpos bloqueadores cd73. |
| CA3149494A1 (en) | 2019-08-12 | 2021-02-18 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells |
| JP7727387B2 (ja) * | 2019-08-27 | 2025-08-21 | エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド | 新規の抗ｃｄ３９抗体 |
| KR20220062500A (ko) | 2019-09-16 | 2022-05-17 | 서피스 온콜로지, 인크. | 항-cd39 항체 조성물 및 방법 |
| CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
| CN114651013B (zh) | 2019-11-05 | 2025-03-14 | 北京加科思新药研发有限公司 | 对cd39具有特异性的结合分子及其用途 |
| WO2022256483A1 (en) * | 2021-06-03 | 2022-12-08 | Surface Oncology, Inc. | Methods of treating cancer with an anti-cd39 antibody and pembrolizumab |
| MX2024010646A (es) * | 2022-03-03 | 2024-09-19 | Arcus Biosciences Inc | Anticuerpos anti-cd39 y uso de los mismos. |
| IL316289A (en) | 2022-04-29 | 2024-12-01 | Purinomia Biotech Inc | Methods and compositions for treating diseases and disorders driven by eosinophils |
| WO2024115935A1 (en) * | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2238170B1 (en) * | 2008-01-31 | 2016-11-23 | INSERM - Institut National de la Santé et de la Recherche Médicale | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
| EP2654789B1 (en) * | 2010-12-22 | 2018-05-30 | Orega Biotech | Antibodies against human cd39 and use thereof |
| DK3424953T3 (en) * | 2011-06-06 | 2020-11-02 | Novo Nordisk As | Terapeutiske antistoffer |
-
2016
- 2016-11-22 CA CA3005986A patent/CA3005986A1/en active Pending
- 2016-11-22 EP EP16800926.4A patent/EP3380519A1/en not_active Withdrawn
- 2016-11-22 JP JP2018526708A patent/JP2019509014A/ja active Pending
- 2016-11-22 US US15/778,202 patent/US20190153113A1/en not_active Abandoned
- 2016-11-22 WO PCT/EP2016/078395 patent/WO2017089334A1/en not_active Ceased
- 2016-11-22 AU AU2016359790A patent/AU2016359790A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019509014A5 (https=) | ||
| ES3038421T3 (en) | Humanized or chimeric cd3 antibodies | |
| US12227569B2 (en) | Humanized antibodies with increased stability | |
| CN109715663B (zh) | 结合生长抑素受体2的异源二聚抗体 | |
| CN101952454B (zh) | 具有减弱的Fc配体亲和性的抗IFNAR1抗体 | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| CA3046082A1 (en) | Antibodies and methods of use thereof | |
| JP2013545455A5 (https=) | ||
| JP2014520788A5 (https=) | ||
| TW202016142A (zh) | 用於治療癌症之組合物及方法 | |
| JP7811176B2 (ja) | Ｃ１９ ｃ３８二特異性抗体 | |
| WO2021173844A1 (en) | C19 c38 bispecific antibodies | |
| JP2023076596A5 (https=) | ||
| RU2019123112A (ru) | Анти-il-5 антитела | |
| TW202509068A (zh) | 結合ox40l之抗體及使用方法 | |
| JP2023511652A (ja) | 鎖間システインが選択的にマッチングされた二重特異性抗体及びその使用 | |
| CN110709417A (zh) | 具有突变人IgG4的多肽 | |
| RU2015129655A (ru) | Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела | |
| EP4417626A1 (en) | Novel antibody-cytokine fusion protein, preparation method therefor and use thereof | |
| US20240352156A1 (en) | Antibodies targeting immunosuppressive b cells | |
| AU2017365367A1 (en) | Monoclonal antibody directed to FGFR1 | |
| JP2024534116A (ja) | 免疫抑制性ｂ細胞と関連付けられる癌を処置する方法 | |
| KR20210116429A (ko) | 이중특이적 항-cd37 항체를 포함하는 제약 조성물 | |
| CA3146977A1 (en) | Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof | |
| WO2018095932A1 (en) | Monoclonal antibody directed to fgfr1 |